|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
WO2011028531A1
(en)
|
2009-08-24 |
2011-03-10 |
Baylor College Of Medicine |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
|
|
HUE049886T2
(hu)
|
2010-05-14 |
2020-10-28 |
Massachusetts Gen Hospital |
Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
|
|
ES2746233T3
(es)
*
|
2011-05-24 |
2020-03-05 |
Biontech Rna Pharmaceuticals Gmbh |
Vacunas individualizadas para el cáncer
|
|
EP3892295B1
(en)
*
|
2011-05-24 |
2023-04-26 |
BioNTech SE |
Individualized vaccines for cancer
|
|
EP2757153B1
(en)
*
|
2011-08-02 |
2019-07-03 |
The University of Tokyo |
Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
|
|
JP2014530013A
(ja)
*
|
2011-09-29 |
2014-11-17 |
トローバジーン インコーポレイテッド |
Ｓｆ３ｂ１遺伝子における変異および慢性リンパ性白血病
|
|
WO2013086464A1
(en)
*
|
2011-12-07 |
2013-06-13 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
WO2013119947A1
(en)
|
2012-02-09 |
2013-08-15 |
Baylor College Of Medicine |
Pepmixes to generate multiviral ctls with broad specificity
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US10640535B2
(en)
|
2012-05-25 |
2020-05-05 |
Agenus Inc. |
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
|
|
MX364370B
(es)
*
|
2012-07-12 |
2019-04-24 |
Persimmune Inc |
Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
AU2013308409A1
(en)
*
|
2012-08-31 |
2015-03-26 |
University Of Birmingham |
Target peptides for immunotherapy and diagnostics
|
|
AU2013312529A1
(en)
|
2012-09-05 |
2015-04-16 |
The University Of Birmingham |
Target peptides for colorectal cancer therapy and diagnostics
|
|
EP2901341B1
(en)
|
2012-09-28 |
2019-04-10 |
The University of Connecticut |
Identification of tumor-protective epitopes for the treatment of cancers
|
|
CA2892391C
(en)
|
2012-11-28 |
2023-10-17 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
ES2739913T3
(es)
|
2013-02-22 |
2020-02-04 |
Curevac Ag |
Combinación de vacunación e inhibición de la ruta PD-1
|
|
EP2958588B1
(en)
|
2013-02-22 |
2017-08-23 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
EP2970907B1
(en)
|
2013-03-14 |
2020-01-01 |
The Johns Hopkins University |
Nanoscale artificial antigen presenting cells
|
|
JP6702855B2
(ja)
*
|
2013-04-07 |
2020-06-03 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
個別化された新生物ワクチンの組成物及び方法
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
EP4052724A1
(en)
*
|
2013-12-06 |
2022-09-07 |
The Broad Institute Inc. |
Formulations for neoplasia vaccines
|
|
BR112016014410A2
(pt)
*
|
2013-12-20 |
2018-02-20 |
The Broad Institute Inc. |
terapia de combinação com vacina de neoantígeno
|
|
US20160326597A1
(en)
*
|
2014-01-02 |
2016-11-10 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
AU2015247727A1
(en)
|
2014-04-15 |
2016-11-03 |
University Of Virginia Patent Foundation |
Isolated T cell receptors and methods of use therefor
|
|
CN107076762B
(zh)
*
|
2014-09-10 |
2021-09-10 |
豪夫迈·罗氏有限公司 |
免疫原性突变体肽筛选平台
|
|
AU2015315559A1
(en)
*
|
2014-09-10 |
2017-02-16 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
WO2016040900A1
(en)
*
|
2014-09-14 |
2016-03-17 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
PT3193917T
(pt)
*
|
2014-09-17 |
2021-10-20 |
Io Biotech Aps |
Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta
|
|
SG11201702191YA
(en)
*
|
2014-09-17 |
2017-04-27 |
Univ Johns Hopkins |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
JP6599450B2
(ja)
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
EP4029508A1
(en)
*
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
WO2016128060A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
EP3273944B1
(en)
|
2015-03-25 |
2024-11-20 |
The Regents of The University of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
WO2016172722A1
(en)
|
2015-04-23 |
2016-10-27 |
Nantomics, Llc |
Cancer neoepitopes
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
WO2016174085A1
(en)
*
|
2015-04-27 |
2016-11-03 |
Cancer Research Technology Limited |
Method for treating cancer
|
|
CA2984234C
(en)
|
2015-05-01 |
2023-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
SG10201912485PA
(en)
|
2015-05-13 |
2020-02-27 |
Agenus Inc |
Vaccines for treatment and prevention of cancer
|
|
BR112017024797A2
(pt)
*
|
2015-05-20 |
2018-08-07 |
The Broad Institute Inc. |
neoantígenos partilhados
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
EP3323070B1
(en)
*
|
2015-07-14 |
2024-05-08 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
EP3328394A4
(en)
*
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
HK1258649A1
(zh)
*
|
2015-09-18 |
2019-11-15 |
Baylor College Of Medicine |
来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
KR102770755B1
(ko)
*
|
2015-10-12 |
2025-02-21 |
난토믹스, 엘엘씨 |
바이러스 네오에피토프 및 이의 용도
|
|
EP3362103B1
(en)
|
2015-10-12 |
2025-01-22 |
Nantomics, LLC |
Compositions and methods for viral cancer neoepitopes
|
|
AU2016339022B2
(en)
*
|
2015-10-12 |
2020-09-10 |
Nantomics, Llc |
Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
|
|
EP3362930A4
(en)
*
|
2015-10-12 |
2019-06-19 |
Nantomics, LLC |
SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
|
|
US20180318409A1
(en)
*
|
2015-10-22 |
2018-11-08 |
Modernatx, Inc. |
Cancer vaccines
|
|
RU2743169C2
(ru)
|
2015-11-06 |
2021-02-15 |
Вентана Медикал Системз, Инк. |
Репрезентативная диагностика
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
SG11201804957VA
(en)
*
|
2015-12-16 |
2018-07-30 |
Gritstone Oncology Inc |
Neoantigen identification, manufacture, and use
|
|
CA3048193A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
|
CA3008437A1
(en)
|
2016-01-08 |
2017-07-13 |
Vaccibody As |
Therapeutic anticancer neoepitope vaccine
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
CN108701172A
(zh)
*
|
2016-02-12 |
2018-10-23 |
南托米克斯有限责任公司 |
高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
|
|
US11585805B2
(en)
|
2016-02-19 |
2023-02-21 |
Nantcell, Inc. |
Methods of immunogenic modulation
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
AU2017281126A1
(en)
*
|
2016-03-24 |
2018-10-04 |
Nant Holdings Ip, Llc |
Sequence arrangements and sequences for neoepitope presentation
|
|
WO2017177207A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene, Llc |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US20190062272A1
(en)
*
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
CA3028721A1
(en)
|
2016-06-20 |
2017-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
AU2017295704B2
(en)
|
2016-07-13 |
2023-07-13 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
HUE056660T2
(hu)
*
|
2016-07-20 |
2022-03-28 |
BioNTech SE |
A neoepitópok mint betegségspecifikus célpontok kiválasztása a fokozott hatékonyságú terápia számára
|
|
EP3493836A4
(en)
*
|
2016-08-02 |
2020-03-04 |
Nantcell, Inc. |
TRANSFECTION OF DENDRITIC CELLS AND RELATED METHODS
|
|
WO2018045249A1
(en)
*
|
2016-08-31 |
2018-03-08 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
WO2018053242A1
(en)
|
2016-09-15 |
2018-03-22 |
Idera Pharmaceuticals, Inc. |
Immune modulation with tlr9 agonists for cancer treatment
|
|
WO2018057447A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
WO2018071796A2
(en)
*
|
2016-10-13 |
2018-04-19 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
EP4338799A3
(en)
*
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
US20190321481A1
(en)
|
2016-11-11 |
2019-10-24 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
AU2017367696A1
(en)
|
2016-12-01 |
2019-06-20 |
Nant Holdings Ip, Llc |
Tumor antigenicity processing and presentation
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
JP7731656B2
(ja)
*
|
2017-02-01 |
2025-09-01 |
モデルナティエックス インコーポレイテッド |
Ｒｎａ癌ワクチン
|
|
AU2018214556A1
(en)
*
|
2017-02-01 |
2019-08-15 |
Modernatx, Inc. |
Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
|
|
WO2018175505A1
(en)
*
|
2017-03-20 |
2018-09-27 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
CN118370809A
(zh)
|
2017-04-03 |
2024-07-23 |
百欧恩泰美国公司 |
蛋白质抗原及其用途
|
|
CA3057715A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
CA3060569A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
|
EP3615675A4
(en)
|
2017-04-24 |
2021-03-03 |
Nantcell, Inc. |
TARGETED NEO-EPITOPIC VECTORS AND ASSOCIATED PROCESSES
|
|
CA3062591A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
|
EP3622068B1
(en)
|
2017-05-10 |
2024-02-28 |
The Broad Institute, Inc. |
Methods for determination of mutations in single replication events
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
EP3630131B1
(en)
*
|
2017-06-02 |
2022-08-31 |
Arizona Board of Regents on behalf of Arizona State University |
A method to create personalized canine cancer vaccines
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
AU2018287159B2
(en)
*
|
2017-06-21 |
2025-01-16 |
Transgene |
Personalized vaccine
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
TWI832820B
(zh)
|
2017-07-21 |
2024-02-21 |
美商伯克利之光生命科技公司 |
抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
|
|
WO2019023269A1
(en)
|
2017-07-25 |
2019-01-31 |
California Institute Of Technology |
DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
|
US20200362418A1
(en)
*
|
2017-10-02 |
2020-11-19 |
Curematch, Inc. |
Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
|
|
RU2020115161A
(ru)
*
|
2017-10-06 |
2021-11-08 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк моноклональных антител против ctla-4 для лечения и профилактики рака
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
JP7357613B2
(ja)
*
|
2017-11-06 |
2023-10-06 |
ラディック インスティテュート フォア キャンサー リサーチ リミテッド |
リンパ球の拡大方法
|
|
EP3706770A4
(en)
*
|
2017-11-07 |
2021-10-27 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
|
|
CN120519386A
(zh)
|
2017-11-08 |
2025-08-22 |
百欧恩泰美国公司 |
T细胞制备组合物和方法
|
|
KR20200090855A
(ko)
|
2017-11-22 |
2020-07-29 |
그릿스톤 온콜로지, 인코포레이티드 |
신생항원에 대한 접합 에피토프 제시 감소
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
CN111818943B
(zh)
|
2018-01-04 |
2024-09-03 |
伊科尼克治疗公司 |
抗组织因子抗体、抗体-药物缀合物及相关方法
|
|
WO2019147921A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
US20210046177A1
(en)
|
2018-01-26 |
2021-02-18 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
KR20200127001A
(ko)
*
|
2018-02-27 |
2020-11-09 |
그릿스톤 온콜로지, 인코포레이티드 |
범-대립유전자 모델을 갖는 신생항원 동정
|
|
TW202012430A
(zh)
|
2018-04-26 |
2020-04-01 |
美商艾吉納斯公司 |
熱休克蛋白質－結合之胜肽組成物及其使用方法
|
|
KR20210018321A
(ko)
*
|
2018-05-25 |
2021-02-17 |
더 위스타 인스티튜트 |
종양 특이적 신생항원 및 이를 사용하는 방법
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
BR112020025764A2
(pt)
|
2018-06-19 |
2021-05-11 |
Biontech Us Inc. |
neoantígenos e usos dos mesmos
|
|
CA3106564A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for breast cancer
|
|
US12391736B2
(en)
|
2018-07-26 |
2025-08-19 |
Curevac Netherlands B.V. |
Off-the-shelf cancer vaccines
|
|
WO2020022901A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for uterine cancer
|
|
IL321692A
(en)
|
2018-07-26 |
2025-08-01 |
Curevac Netherlands B V |
Cancer vaccines for colorectal cancer
|
|
CA3106567A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
CA3106574A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
CN112930569B
(zh)
|
2018-08-31 |
2025-10-03 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
TW202028224A
(zh)
*
|
2018-09-17 |
2020-08-01 |
德商英麥提克生物技術股份有限公司 |
B*44限制肽在抗癌免疫治療的用途和相關方法
|
|
TW202027761A
(zh)
|
2018-09-21 |
2020-08-01 |
美商柏克萊燈光有限公司 |
功能化孔盤、其製備方法及用途
|
|
SG11202101965QA
(en)
|
2018-09-27 |
2021-04-29 |
Vaccibody As |
Method for selecting neoepitopes
|
|
EP3867353A4
(en)
|
2018-10-18 |
2022-07-27 |
Berkeley Lights, Inc. |
PROTO-ANTIGEN PRESENTING SYNTHETIC SURFACES, ACTIVATED T-CELLS AND THEIR USES
|
|
US20200188435A1
(en)
|
2018-11-08 |
2020-06-18 |
Nexlmmune, Inc. |
T cell compositions with improved phenotypic properties
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
MX2021010089A
(es)
|
2019-02-20 |
2021-12-10 |
Rubius Therapeutics Inc |
Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso.
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
WO2020185010A1
(ko)
*
|
2019-03-12 |
2020-09-17 |
(주)신테카바이오 |
인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
|
|
EP3963335B1
(en)
*
|
2019-05-03 |
2024-08-21 |
Epivax Therapeutics, Inc. |
Neoantigens in cancer
|
|
EP3966323A4
(en)
*
|
2019-05-06 |
2024-04-24 |
The Regents Of The University Of Michigan |
TARGETED THERAPY
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
JP7457733B2
(ja)
|
2019-05-30 |
2024-03-28 |
グリットストーン バイオ インコーポレイテッド |
改変アデノウイルス
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
US20230212243A1
(en)
*
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
|
US20230210968A1
(en)
|
2020-06-11 |
2023-07-06 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
CA3187258A1
(en)
|
2020-08-06 |
2022-02-10 |
Karin Jooss |
Multiepitope vaccine cassettes
|
|
AU2021325081A1
(en)
|
2020-08-13 |
2023-04-13 |
Biontech Us Inc. |
T cell manufacturing compositions and methods
|
|
GB2613718A
(en)
*
|
2020-08-31 |
2023-06-14 |
World Biotech Regenerative Medical Group Ltd |
Personalized immunogenic compositions and methods for producing and using same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
EP4313129A4
(en)
*
|
2021-03-26 |
2025-05-14 |
The Translational Genomics Research Institute |
METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES
|
|
EP4330380A1
(en)
|
2021-04-30 |
2024-03-06 |
Tigen Pharma SA |
Single vessel expansion of lymphocytes
|
|
WO2022251034A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Amazon Technologies, Inc. |
Multicomponent chemical composition of a peptide-based neoantigen vaccine
|
|
WO2023025404A1
(en)
|
2021-08-24 |
2023-03-02 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4612276A1
(en)
|
2022-11-02 |
2025-09-10 |
Tigen Pharma SA |
Expansion of lymphocytes
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|